机构名称：
¥ 1.0
肥胖症的流行率，因此，近几十年来，随着未来几年的这种趋势维持这种趋势。因此，迫切需要新的疗法来帮助我们修改这一轨迹。Tirzepatide, the first of a new pharmacological class called co-agonists or double agonists of glucagon--like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), demonstrated in clinical trials published in the last two years, significantly reduce blood glucose, to reduc to insulin resistance and reduce the insulin and reduce the insulin and reduce the resistance and reduce the insulin and reduce Body weight, with additional benefits in hypertension and lipid profile.预计其非血管终点的结果预计将是巨大的预期。在本文中，对这种药物进行了综述，以及在糖尿病和肥胖症治疗的未来中出现的观点。
tirzepatide-内科杂志
主要关键词
相关文件推荐
